[Featured Stock] Curiox, 20 Trillion Cell Analysis 'Game Changer'... 15x Processing Capacity ↑ Price Competitiveness ↑↑

Curiox Biosystems is showing strong performance. The company is gaining attention for possessing essential technology for the mass production of cell and gene therapies (CGT).

As of 9:42 AM on the 30th, Curiox Biosystems is trading at 25,000 KRW, up 6.61% from the previous day.

It takes about 10 to 14 days to produce CAR-T therapies, and the daily cell analysis process relies entirely on manual labor. Industry insiders expect that introducing automation processes will enable standardization and mass production of cell and gene therapies.

Curiox Biosystems succeeded in developing and commercializing the world's first automated cell analysis process equipment. Recently, the company partnered with global life science equipment firm Levity to begin production of the next-generation cell analysis product, "Pluto." Levity, listed on the New York Stock Exchange, has a market capitalization of approximately 20 trillion KRW.

Nam-Yong Kim, CEO of Curiox Biosystems, stated in a recent interview with the media, "Signing an OEM contract with Levity means that a relatively unknown technology company has laid the foundation to enter the global market."

The products mass-produced by Curiox through Levity include the ‘Pluto LT’ and the soon-to-be-released follow-up models ‘Pluto MT’ and ‘Pluto HT.’ Pluto has increased the maximum processing capacity per well of a plate to about 2000 ul (microliters). Considering that the previous product handled 135 ul, this is nearly a 15-fold increase.

The price per device is around 50,000 USD, which is affordable. The company stated that the market size for Curiox equipment is expected to expand to about 20 trillion KRW by adding the whole blood analysis market (10 trillion KRW) to the existing general cell analysis market (9 trillion KRW).

Product demonstrations are being conducted for potential large-volume order customers. It is known that a global major clinical research organization (CRO) has shown interest. CEO Kim emphasized, "Both our clients and we aim to complete the demos within this year," adding, "If contracts with global CROs follow, many CRO companies will adopt Curiox solutions to enhance their competitiveness."

Min-Soo Shin, a researcher at Kiwoom Securities, explained, "There was never any disagreement about the technology, and the main reason for the slow growth in performance was the high price of the equipment," adding, "They are launching an affordable, cost-effective model that sells at a reasonable price compared to existing equipment."

He continued, "Curiox has signed a non-exclusive co-selling agreement for Beckman Coulter Life Sciences’ cell analysis process," expressing expectations that "this will open sales channels and, since it is a non-exclusive contract, it can be presented as a reference when collaborating with other pharmaceutical partners." Beckman Coulter is one of the core subsidiaries of Danaher, which has a market capitalization of about 242 trillion KRW.